| 1.5 -0.02 (-1.32%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.92 | 1-year : | 2.09 |
| Resists | First : | 1.64 | Second : | 1.78 |
| Pivot price | 1.49  |
|||
| Supports | First : | 1.4 | Second : | 1.17 |
| MAs | MA(5) : | 1.49 | MA(20) : | 1.51  |
| MA(100) : | 1.82 |
MA(250) : | 1.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 29 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 2.71 | Low : | 1.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IPHA ] has closed below upper band by 49.3%. Bollinger Bands are 44.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.53 |
| Low: | 1.45 - 1.46 | 1.46 - 1.47 |
| Close: | 1.49 - 1.5 | 1.5 - 1.51 |
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Wed, 28 Oct 2026
Innate Pharma S.A. (IPHA) stock price, news, quote and history - Yahoo Finance Australia
Tue, 27 Oct 2026
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 - Quantisnow
Wed, 21 Oct 2026
New York and London conferences await Innate Pharma (IPHA) executives in November 2026. - Stock Titan
Wed, 21 Oct 2026
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference - Business Wire
Thu, 08 Oct 2026
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround - Yahoo Finance
Wed, 23 Sep 2026
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 112 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 89 (K) |
| Shares Short P.Month | 82 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.5 |
| Profit Margin | 0 % |
| Operating Margin | -335.8 % |
| Return on Assets (ttm) | -46.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 16.5 % |
| Gross Profit (p.s.) | -0.28 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -2.55 |
| PEG Ratio | 0 |
| Price to Book value | -3.07 |
| Price to Sales | 17.07 |
| Price to Cash Flow | -3.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|